ProBioGen AG has signed a second antibody development project with Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.   Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process ...